Welcome to the first issue of Renal Cancer Research Review
Issue 1, 2018.
We lead this issue with a sub-group analysis of the ASSURE trial exploring retroperitoneal lymphadenectomy for high risk, nonmetastatic renal cell carcinoma. The group conclude there was no overall survival benefit for lymphadenectomy relative to no lymphadenectomy. Another study investigated survival outcomes for patients with localised upper tract urothelial carcinoma managed with non-definitive treatment. The authors reported median overall survival was significantly shorter in the non-surgical compared to the surgical cohort (1.9 vs 7.8 years respectively). A pooled analysis of SABR found it to be well tolerated and locally effective for treating patients who have primary renal cell carcinoma. SABR also had an acceptable impact on renal function.
A number of the articles included in this issue have a focus on immunotherapy. A phase III trial compared cabozantinib to everolimus in patients with advanced renal cell carcinoma following prior VEGF targeted therapy. Cabozantinib compared to everolimus improved progression-free survival, overall survival and objective response rate. The safety profile was also acceptable. An article reports the safety and efficacy results from the phase I CheckMate 016 study of nivolumab plus ipilimumab in metastatic renal cell carcinoma. The researchers concluded the combination therapy demonstrated antitumor activity with manageable safety and durable responses. In addition, the overall survival data was promising. The concluding paper presents the pooled results from two expansion cohorts of the JAVELIN study. Avelumab showed antitumour activity in the treatment of patients with platinum-refractory metastatic urothelial carcinoma. In addition the safety profile was manageable. The authors note avelumab has received accelerated US FDA approval in this setting.
I hope you find the research in this issue useful to you in your practice and I look forward to your comments and feedback.
Dr Richard Haddad